国际血栓与止血学会基于GRADE方法的先天性血友病A和B治疗临床实践指南
国际血栓与止血学会组建多学科指南小组,按GRADE方法制定先天性血友病A和B治疗指南,共确定13个临床问题(血友病A 11个、血友病B 2个),全部13条推荐均达成一致;对重度和中度重度血友病A和B,强推荐预防治疗优于按需治疗,其余问题仅给出条件推荐。
要点
- 对重度和中度重度血友病A和B,强推荐预防治疗优于按需治疗。
- 其余问题仅给出条件推荐,未给出强推荐。
- 13条推荐中7条(54%)基于随机临床试验证据,3条(23%)基于观察性研究,3条(23%)基于间接比较。
核心结论
- 对重度和中度重度血友病A和B,强推荐预防治疗优于按需治疗;其余问题仅给出条件推荐。
- 未来研究应聚焦直接治疗比较以及伴和不伴抑制物的血友病B治疗。
研究设计与样本
- 国际血栓与止血学会组建具有全球代表性的医师和患者多学科指南小组,平衡利益冲突以减少潜在偏倚。
- 小组按对临床医师和患者的重要性优先确定临床问题与结局,方法学团队支持证据检索和系统评价,采用GRADE方法及证据到决策框架,推荐草案接受公众评议。
- 共选定13个问题:11个涉及血友病A治疗,2个涉及血友病B治疗。
主要发现
- 血友病A问题涉及FVIII浓缩物、旁路制剂和非因子治疗(emicizumab)的预防与按需治疗(伴和不伴抑制物)以及免疫耐受诱导。
- 血友病B问题涉及FIX浓缩物预防治疗和按需治疗出血事件。
- 13条推荐全部达成一致,其中7条(54%)基于随机临床试验证据,3条(23%)基于观察性研究,3条(23%)基于间接比较。
关键数值与推荐
- 对重度和中度重度血友病A和B:强推荐预防治疗优于按需治疗。
- 其余问题:仅给出条件推荐。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hemophilia is a rare congenital bleeding disorder that results from complete or partial deficiency of blood coagulation factor (F)VIII (hemophilia A) or FIX (hemophilia B) due to pathogenic variants in their coding genes. Hemophilia requires complex management. To date, there is no evidence-based clinical practice guideline on hemophilia treatment based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. OBJECTIVES: This evidence-based clinical practice guideline from the International Society on Thrombosis and Haemostasis aims to provide an overview of evidence and support patients, caregivers, hematologists, pediatricians, other clinicians, researchers, and stakeholders in treatment decisions about congenital hemophilia A and B. METHODS: The International Society on Thrombosis and Haemostasis formed a multidisciplinary guideline panel of physicians and patients with global representation, balanced to minimize potential bias from conflicts of interest. The panel prioritized a set of clinical questions and outcomes according to their importance for clinicians and patients. A methodological team supported the guideline development process, including searching for evidence and performing systematic reviews. The GRADE approach was used, including GRADE Evidence to Decision frameworks. The recommendations were subject to public comment. RESULTS: The panel selected 13 questions, of which 11 addressed the treatment of hemophilia A and 2 the treatment of hemophilia B. Specifically, the panel addressed questions on prophylactic and episodic treatment with FVIII concentrates, bypassing agents, and nonfactor therapy (emicizumab) for hemophilia A (with and without inhibitors) as well as immune tolerance induction for hemophilia A. For hemophilia B, the panel addressed questions on prophylactic and episodic treatment of bleeding events with FIX concentrates. Agreement was reached for all 13 recommendations, of which 7 (54%) were based on evidence from randomized clinical trials, 3 (23%) on observational studies, and 3 (23%) on indirect comparisons. CONCLUSION: Strong recommendations were issued for prophylactic over episodic treatment for severe and moderately severe hemophilia A and B. Only conditional recommendations were issued for the remaining questions. Future research should focus on direct treatment comparisons and the treatment of hemophilia B with and without inhibitors. Future updates of this guideline will provide an updated evidence synthesis on the current questions and focus on new FVIII and FIX concentrates, novel nonfactor therapies, and gene therapy for severe and nonsevere hemophilia A and B.
引用
- Rezende SM, Neumann I, Angchaisuksiri P, et al. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology. J Thromb Haemost. 2024. PMID: 39043543. doi:10.1016/j.jtha.2024.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。